Furthermore, the option to continue or initiate new AD medication during the trial, including the amyloid lowering monoclonal antibodies, was not a randomization stratification factor and may therefore act as a confounding factor if their use across treatment arms is unequal
doi:10.1001/jamaoncol.2025.2681 Gruber J, Soares dos Santos B, Maro M, et al
Tirzepatide followed as Mounjaro and Zepbound, engaging an additional gut hormone receptor and producing larger average reductions in published trials
Toxicology studies have shown no lethal dose (LD1) could be achieved in animal models, suggesting a wide therapeutic window
The FDA warning does not extend to family history of other thyroid cancer types, such as papillary or follicular carcinoma, which have different cellular origins and pathophysiology
Sterile water can be used for single-dose vials that will be used immediately and then discarded